Clinical Trial Update: Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial at University of Wisconsin–Madison evaluating androgen deprivation with or without pTVG-AR and with or without T-cell checkpoint bloc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• T-cell checkpoint blockade
• pTVG-AR (pTVG-AR)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING